Sequential tislelizumab plus bronchial arterial chemoembolization and systemic chemotherapy in advanced NSCLC with bulky tumors: efficacy and safety - Takeaways - MDSpire

Sequential tislelizumab plus bronchial arterial chemoembolization and systemic chemotherapy in advanced NSCLC with bulky tumors: efficacy and safety

  • By

  • Yaping Quan

  • Zhengjie Liang

  • Yunhao Wei

  • Hao Li

  • Yan Zeng

  • Jie Shen

  • Shengfa Su

  • Xian Liu

  • Zhongjun Huang

  • Minfang Wang

  • Hongyan Luo

  • Yong Hu

  • Jie Peng

  • July 15, 2026

Share

  • 1

    The study analyzed 68 patients with advanced NSCLC and bulky tumors, comparing two treatment regimens involving tislelizumab.

  • 2

    Group A received tislelizumab plus bronchial arterial chemoembolization followed by systemic chemotherapy, while Group B received tislelizumab and chemotherapy alone.

  • 3

    Group A demonstrated a significantly higher objective response rate of 79.41% compared to 44.12% in Group B (p = 0.006).

  • 4

    Median progression-free survival was significantly longer in Group A at 12.47 months versus 7.73 months in Group B (p = 0.024).

  • 5

    The safety profile was manageable, with the most common grade 3 or higher treatment-related adverse events being neutropenia, anemia, and thrombocytopenia.

Original Source(s)

Sequential tislelizumab plus bronchial arterial chemoembolization and systemic chemotherapy in advanced NSCLC with bulky tumors: efficacy and safety

  • by Yaping Quan, Zhengjie Liang, Yunhao Wei, Hao Li, Yan Zeng, Jie Shen, Shengfa Su, Xian Liu, Zhongjun Huang, Minfang Wang, Hongyan Luo, Yong Hu, Jie Peng

  • July 15, 2026

Related Content

Evaluation of an interpretable deep-learning model for the automated plan review of intensity-modulated radiation therapy

Efficacy and safety of bupleurum-containing formulas combined with chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis

Feasibility and acceptability of FinCare: A personalized online tool for estimating out-of-pocket costs for cancer treatment